RegulatoryJun 12, 2026, 05:31 PM
Traws Pharma Defers Influenza Study Due to Negative UK Regulatory Review
AI Summary
Traws Pharma, Inc. announced the deferral of its planned Phase 2a human influenza challenge study for tivoxavir marboxil. This decision follows a negative review of the program by the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA). Despite this setback, the company remains committed to advancing long-acting influenza antivirals, noting tivoxavir marboxil's potential for emergency use in bird flu outbreaks and is actively developing alternative candidates. The company's cash runway is projected to extend to Q1 2027.
Key Highlights
- Traws Pharma deferred the Phase 2a human influenza challenge study for tivoxavir marboxil.
- The deferral is due to a negative review of the program by the UK's MHRA.
- Tivoxavir marboxil showed potent efficacy in three animal models of highly pathogenic avian influenza.
- The company is actively advancing alternative influenza antiviral candidates.
- Traws Pharma's cash runway extends to Q1 2027.
- The company remains committed to advancing long-acting influenza antivirals.
Price Impact
More from TRAW